Disentangling the contribution of weight loss and diet composition on glycaemia in type 2 diabetes

niversity of Oxford0 个研究点目标入组 30 人开始时间: 2024年4月17日最近更新: 2024年5月13日

试验速览

暂无简介。

•1.Participants willing and able to give informed consent.
•2.Adult male or female, aged 18-70 years old.
•3.Diagnosed with current type 2 diabetes (i.e. not in remission).
•4.BMI of > = 27kg/m².
•5.Has a smartphone with internet access and compatible with continuous glucose monitoring (CGM) technology, and participant is willing and able to use this.
•6.Is willing and able to change their diet for the study period.
•7.Willing to pause one or more usual medications if required for duration of study.

•1.Pregnant, breastfeeding, or planning to become pregnant during the course of the study.
•2.Recent weight loss (> 2kg in last 4 weeks; self-reported).
•3.People who are already following a specific restricted diet.
•4.Are currently taking more than two prescribed medications for diabetes glycaemic control.
•5.People with HbA1c > = 87 mmol/mol.
•6.Are currently using insulin therapy, SGLT2 inhibitors (Gliflozins – eg empaglifozin, dapagliflozin, canagliflozin), or GLP-1 agonists (e.g. exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide).
•7.Previous or current eating disorder (or any other psychological condition) that may affect the participant’s ability to adhere to study intervention/experimental diets.
•8.Recent myocardial infarction or stroke (< 3 months).
•9.Renal failure (chronic kidney disease stage 4 or 5).
•10.Current active treatment for cancer (other than skin cancer treated with curative intent by local treatment only).
•11.Proliferative diabetic retinopathy, or maculopathy.
•12.GP feels inappropriate to take part in study (e.g. unable to attend study visits; end of life care, or would not benefit from weight loss or improved diabetes control).
•13.Most recent (non-fasting or fasting) triglyceride level > 5 mmol/l.

发起方